Patients Stopping Slimming Jabs Regain Weight Four Times Faster Compared to People Using Diet and Exercise

Fresh analysis reveals that people who discontinue new weight-loss injections like Mounjaro or Wegovy may regain shed pounds much more quickly than those who stop traditional diet and exercise plans.

Research printed in a major health publication points out that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month after stopping.

"Users using these drugs need to be informed of the danger of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.

That rate of recovery means a return to starting mass in about 18 months.

Weighing Approaches

The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.

Researchers emphasize that individuals who lose weight through diet and exercise usually see a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.

Explaining the Fast Regain

Doctors believe the mode of action of the drugs explains the accelerated weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.

"Long-term administration of GLP-1 levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making overeating a significant risk."

A Lifelong Condition?

Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.

Many experts contend that, considering the significant potential of weight regain, the therapy should be considered life-long.

This view is reinforced by drug manufacturers, who say that the findings "emphasize the persistent character of excess weight," similar to managing conditions like hypertension.

Patient Testimonies

People who have stopped the jabs describe a powerful return of appetite.

"I experienced a trigger that goes on and I was suddenly starving," recalled a patient.

This difficulty is worsened if users have not established sustainable lifestyle or habit modifications during therapy.

Widespread Adoption

Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is more common among females compared to men.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Finally, clinicians stress that while these medications are powerful tools for weight loss, they are not a magic fix and long-term success likely depends on combined behavioural support.